Multiple Myeloma Clinical Trials

Find Multiple Myeloma Clinical Trials Near You

One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

By detailed sequence analysis and subsequent biophysical characterization of prototypic light chains, this project aims to identify sequence fingerprints in IGLV1-44 light chains leading to AL amyloidosis and POEMS syndrome. This understanding might help improve the risk stratification and early diagnosis of patients overexpressing pathologic IGLV1-44 LCs. Moreover, the development of nanobodies efficient in recognizing and stabilizing IGLV1-44 light chains which exert direct toxicity in cardiac AL amyloidosis and POEMS syndrome might form the basis for future development of therapeutic agents capable of counteracting IGLV1-44 light chain proteotoxicity.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 99
Healthy Volunteers: f
View:

• Biopsy-proven diagnosis of systemic AL amyloidosis, POEMS syndrome or multiple myeloma

• Planned peripheral blood sampling +/- bone marrow aspiration

• Age \> 18 years

• Willingness to allow use of clinical data and diagnostic leftovers of clinical specimens for research purposes through signing a written informed consent.

Locations
Other Locations
Italy
Fondazione IRCCS Policlinico San Matteo
RECRUITING
Pavia
Contact Information
Primary
Mario Nuvolone, MD
m.nuvolone@smatteo.pv.it
0382502935
Time Frame
Start Date: 2025-11-28
Estimated Completion Date: 2026-06-30
Participants
Target number of participants: 100
Sponsors
Leads: Fondazione IRCCS Policlinico San Matteo di Pavia

This content was sourced from clinicaltrials.gov